Clinical trial NCT06044740: Sevoflurane's Effect on Neurocognition Study
Official title: Sevoflurane's Effect on Neurocognition Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Anesthesia
Pain
Amnesia
Keywords: functional MRI
sevoflurane
electric nerve stimulation
sedation
functional connectivity
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: National Institute of General Medical Sciences (NIGMS)
First posted: 2023-09-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose sevoflurane. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.

Detailed description: This is a non-randomized, clinical trial study of healthy volunteer subjects, which will employ neuroimaging and behavioral measures to characterize the effects of inhalational sevoflurane on pain processing and cognitive function. Sedative doses of sevoflurane will be targeted, and steady-state end-tidal (expired) concentrations achieved, while subjects perform a pain and memory cognitive task. At both no-drug baseline and the targeted doses, task and resting-state functional magnetic resonance imaging (MRI) scans will be acquired, and this data will be analyzed subsequently for task-related brain activity(from pain processing and memory formation) and functional connectivity. This work will use a systems neuroscience approach to fill an important knowledge gap about the central effects of inhalational sevoflurane in the context of painful stimulation.

The investigators propose to complete the following 3 Aims, at a sedative dose of Sevoflurane, compared to no-drug baseline, using functional MRI:

Aim 1: Determine how the brain response to acute pain stimulation is modulated by sevoflurane. It is anticipated that sevoflurane will correlate to decreased activation in both somatosensory (thalamus, insula, primary somatosensory/motor) and affective (anterior cingulate) components of the pain processing brain areas.

Aim 2: Determine how memory encoding is modulated by sevoflurane, in the context of periodic painful stimulation. It is anticipated that sevoflurane will correlate to decreased activation in both the explicit memory (hippocampus, parahippocampus) and associative learning (amygdala, anterior cingulate) brain systems.

Aim 3: Determine the neural effects of inhalational sevoflurane on brain connectivity both at rest and during the combined pain and memory task performance. It is anticipated that hypothesize that sevoflurane will cause widespread dose-dependent decreases in long-range functional connectivity between brain areas known to be involved in pain processing and to the default mode network, and that this connectivity will differ between the resting (task-free) and periodic pain states.

Eligibility criteria: Inclusion Criteria:

* Adults, age 18-59, who are native English speakers with at least a high school education
* have normal hearing and memory
* be of normal body-weight
* be generally healthy (free from significant chronic disease)
* have none of the specific exclusion criteria
* have a valid email address and valid phone number throughout the study
* anticipate ability to participate in all visits required for the phase of the study in which they are enrolled

Exclusion Criteria:

* being pregnant or attempting to conceive
* having a body mass index (BMI) \> 35
* having significant memory impairment or hearing loss
* having sleep apnea
* having chronic pain or frequently taking pain medication (including tramadol)
* having any severe or poorly-controlled medical problem (hypertension, diabetes)
* having neurologic or psychiatric disease, including anxiety, and depression
* having significant cardiac valvular disease or cardiomyopathy
* having a history of abnormal heartbeats (cardiac conduction abnormality or arrhythmia)
* having a history of seizures or convulsions
* having a history of liver disease
* having a history of asthma or other significant pulmonary disease
* having a history of malignant hyperthermia, muscular dystrophy, central core disease, or hyperkalemia
* being claustrophobic
* have metal implants or non-removable metal piercings
* having a history of adverse reaction to anesthetics
* daily alcohol or heavy alcohol use; history of alcohol abuse
* current daily smoker
* regular or recent marijuana use (including prescribed/medical marijuana)
* illicit drug use
* regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
* current use of selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors (MAOIs) and some other specific drugs phenytoin, carbamazepine, and rifampin
* history of QT prolongation
* hypersensitivity or allergic reaction to ondansetron (Zofran)

Primary outcomes:
measure: functional magnetic resonance imaging activation in response to experimental tasks
timeFrame: Visit 1: Immediate; average activity, calculated from each task scan
measure: Functional connectivity
timeFrame: Visit 1: Immediate; brain activity captured in data acquired across entire 6-8 minute scan.
Secondary outcomes:
measure: Explicit memory performance
timeFrame: Visit 2: 24-hrs post-learning experiment
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Keith M Vogt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: